Hsu Pang-Kuei, Pan Frank F C, Hsieh Ching-Sen
Greenyn Biotechnology Co., Ltd., Taichung City 40768, Taiwan.
Department of Pharmacy and Department of Hospitality, College of Pharmacy and Healthcare, Tajen University, Yanpu, Pingtung County 90741, Taiwan.
Nutrients. 2020 Apr 28;12(5):1252. doi: 10.3390/nu12051252.
This study was conducted to test the effectiveness of a particular bitter melon peptide (BMP), with a specific sequence of 19 amino acids (mcIRBP-19), in regulating diabetic patients' blood glucose. In order to test the product with the specially processed BMP, a total of 142 diabetic patients were solicited as study subjects, of which 64 were assigned to an experiment group and 78 to a control group. Biochemical data were compared with a paired test to verify the significance of changes over different time periods. The clinical results showed that BMP started to improve the subjects' glycated hemoglobin (HbA1c) levels at the end of the second month (T2), with mean values being significantly lowered from 7.8 ± 1.4% (T0) to 7.5 ± 1.4% (T2) ( = 0.004). The values reduced continuously, eventually reaching 7.4 ± 1.1% ( = 0.000) at the end of the experiment (T3). HbA1c levels for the control group were 7.5 ± 1.2% in T0 and 7.5 ± 1.1% (T3), and not significantly different ( = 0.852) over the same period. This study provides clinical evidence that helps to verify the effectiveness of the new BMP product in regulating diabetic patients' blood sugar levels.
本研究旨在测试一种特定的苦瓜肽（BMP），其具有19个氨基酸的特定序列（mcIRBP - 19），对糖尿病患者血糖的调节效果。为了测试经过特殊处理的BMP产品，共招募了142名糖尿病患者作为研究对象，其中64人被分配到实验组，78人被分配到对照组。通过配对检验比较生化数据，以验证不同时间段变化的显著性。临床结果表明，BMP在第二个月末（T2）开始改善受试者的糖化血红蛋白（HbA1c）水平，平均值从7.8±1.4%（T0）显著降低至7.5±1.4%（T2）（ = 0.004）。该值持续降低，在实验结束时（T3）最终达到7.4±1.1%（ = 0.000）。对照组的HbA1c水平在T0时为7.5±1.2%，在T3时为7.5±1.1%，在同一时期无显著差异（ = 0.852）。本研究提供了临床证据，有助于验证新型BMP产品在调节糖尿病患者血糖水平方面的有效性。
